



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Statement of Standalone Audited Financial Results for the Quarter and Year Ended March 31, 2026

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
		Audited	Unaudited	Audited	Audited	Audited
	Income					
I	Revenue from Operations	2,765.28	2,064.40	1,841.09	8,278.75	6,964.85
II	Other Income	34.78	26.11	29.75	114.87	98.15
III	Total Income	2,800.06	2,090.51	1,870.84	8,393.62	7,063.00
	Expenses					
	a) Cost of Materials Consumed	833.61	772.98	1,015.31	2,651.18	2,324.36
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	219.66	(160.98)	(467.05)	(110.89)	(212.59)
	d. Employee benefit expenses	248.17	246.94	209.77	966.80	805.19
	e. Finance Cost	4.68	4.94	4.17	18.89	16.86
	f. Depreciation & amortisation expense	84.98	68.21	60.81	284.09	204.44
	g. Other expenditure	487.67	484.64	407.21	1,831.18	1,439.93
IV	Total Expenses	1,878.77	1,416.73	1,230.22	5,641.25	4,578.19
V	Profit/(loss) before Exceptional Items & Tax (III - IV)	921.29	673.78	640.62	2,752.37	2,484.81
VI	Exceptional Items	-	(4.58)	-	(4.58)	-
VII	Profit/(loss) before Tax (V-VI)	921.29	669.20	640.62	2,747.79	2,484.81
VIII	Tax Expense					
	a) Current Tax	204.16	153.24	127.72	614.33	566.57
	b) Deferred Tax	(25.16)	19.21	9.08	42.26	38.66
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	742.29	496.75	503.82	2,091.20	1,879.58
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	742.29	496.75	503.82	2,091.20	1,879.58
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	0.55	0.54	1.16	(1.33)	(1.67)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.14)	(0.14)	(0.29)	0.34	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	742.70	497.15	504.69	2,090.21	1,878.33
XVI	Earnings per equity Share (for continuing operation):					
	(1) Basic (In ₹)	9.22	6.17	6.29	25.98	23.35
	(2) Diluted (In ₹)	9.22	6.17	6.29	25.98	23.35
XVII	Earnings per equity Share (for discontinued operation):					
	(1) Basic (In ₹)	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):					
	(1) Basic (In ₹)	9.22	6.17	6.29	25.98	23.35
	(2) Diluted (In ₹)	9.22	6.17	6.29	25.98	23.35

[Handwritten Signature]

SUPRIYA LIFESCIENCE LTD.
MUMBAI

See accompanying notes to the financial statements:

Notes:-

1. The audited standalone financial results of the Company for the quarter ended March 31, 2026 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.

2. The above audited standalone financial results of the Company for the quarter ended March 31, 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on May 27, 2026.

3. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes, among other things, setting a uniform definition of wages. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations.

The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 4.58 millions towards employee benefits during the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to and the impact of these will be accounted in accordance with applicable accounting standards.

4. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.

5. The Board of Directors at their meeting dated May 27, 2026 has recommended a final dividend of INR 1/- per equity share (50% on the face value INR 2/- each), subject to approval of shareholders at the ensuing Annual General Meeting.

6. The company does not have any subsidiary/associate/joint venture company as on March 31, 2026.

7. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

8. The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subjected to audit.

Place :- Mumbai
Date :- May 27, 2026

For Supriya Lifescience Limited



Dr. Satish Waman Wagh
Chairman and Executive Director
DIN: 01456982



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

Standalone Balance Sheet as at March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2026	March 31, 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	6,833.17	4,468.32
(b) Right to Use Asset	45.23	46.45
(c) Capital Work in progress	355.48	1,480.15
(d) Intangible Assets	13.12	13.89
(e) Financial Assets		-
(i) Investments	985.23	632.41
(ii) Loans and Advances	-	-
(f) Other Non- Current Assets	15.81	111.54
Total Non-current assets	8,248.04	6,752.76
Current assets		
(a) Inventories	1,595.97	1,183.49
(b) Financial Assets		-
(i) Loans and Advances	5.69	9.27
(ii) Trade receivables	2,194.48	1,343.62
(iii) Cash and cash equivalents	375.46	760.57
(iv) Bank balances other than (iii) above	413.21	30.97
(v) Other Financial Assets	-	7.11
(c) Other current assets	738.22	1,085.68
Total Current Assets	5,323.03	4,420.71
TOTAL ASSETS	13,571.07	11,173.47
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	160.97	160.97
(b) Other equity	11,816.36	9,806.63
Total Equity	11,977.33	9,967.60
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities		
(i) Lease Liabilities	51.89	50.57
(ii) Other financial liabilities	-	-
(b) Provisions	18.97	13.18
(c) Deferred tax Liabilities	312.44	270.18
Total Non-Current Liabilities	383.30	333.93
Current liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	2.46	3.23
(ii) Trade payables		
- Micro Enterprises and Small Enterprises	170.01	-
- Other than micro and small enterprises	938.46	745.46
(iii) Other financial liabilities	20.40	17.59
(b) Provisions	16.71	11.93
(c) Other current liabilities	62.40	93.73
Total Current Liabilities	1,210.44	871.94
TOTAL EQUITY AND LIABILITIES	13,571.07	11,173.47



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

Cash flow statement for the period ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2026	March 31, 2025
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	2,747.79	2,484.80
Adjustments for		
Depreciation and Amortization	284.09	204.44
Interest Income (Net of Expenses)	(94.54)	(78.85)
Dividend Received	(0.00)	(0.05)
Employee Benefit	9.24	11.75
Loss on Sale of fixed Assets	0.09	0.06
Operating profit before working capital changes	2,946.67	2,622.15
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	(850.85)	(226.79)
Inventories	(412.48)	(331.00)
Other Non Current & Current Assets	443.18	67.15
Other Non Current & Current Financial Assets	7.11	37.97
Loans and Advances	3.58	(0.30)
	(809.46)	(452.97)
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	363.01	149.76
Other Non Current & Current Financial Liabilities	2.80	1.85
Other Non Current & Current liabilities	(31.34)	(82.25)
	334.47	69.36
(Income tax paid)/net of refund	(613.99)	(591.79)
Net Cash generated from Operating Activities (A)	1,857.69	1,646.75
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(1,522.35)	(1,623.76)
(Purchase)/ Sale of Investments	(352.82)	5.56
Interest Income	113.43	95.71
Dividend Received	0.00	0.05
Net Cash generated/(outflow) from Investing Activities (B)	(1,761.74)	(1,522.44)
C CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	-	-
Finance Cost	(18.89)	(16.86)
Dividend Paid	(80.48)	(64.39)
Repayment of Lease liability	0.55	(1.08)
Net Cash generated from Financing Activities (C)	(98.82)	(82.33)
Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	(2.87)	41.98
Cash and Cash Equivalents at the end of previous period	791.54	749.56
Cash and Cash Equivalents as at the end of the reporting period	788.67	791.54

